Form 4/A for TRDA Entrada Therapeutics, Inc.
Accepted 2023-04-19 00:00:00 ET · period of report 2023-03-01 · accession 0001689375-23-000028 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DA | 2023-04-19 | 2023-03-01 | TRDA | WENTWORTH KORY JAMES | CFO | A - Grant | $0.00 | +14.2K | 28.0K | +103% | $0 |
| DA | 2023-04-19 | 2023-03-01 | TRDA | WENTWORTH KORY JAMES | CFO | A - Grant | $0.00 | +21.5K | 21.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-01 | A | A | 14,200 | $0.00 | 27,957 | D | — | — | (F1) Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2024; (ii) 25% on March 1, 2025; (iii) 25% on March 1, 2026 and (iv) the remaining 25% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. (F2) The Reporting Person's original Form 4, filed on March 3, 2023, is being amended by this Form 4A solely to correct an administrative error, which misreported a grant that occurred on March 1, 2023 as a total of 43,000 option shares and 28,400 RSUs, when in fact 21,500 option shares and 14,200 RSUs were granted as of that date, accurately reflecting that these grants are semi-annual. As a result of this administrative error, the number of shares beneficially owned by the Reporting Person following the corrected transaction reflects a reduction by 50% in the number of RSUs and option shares, respectively, reported as beneficially owned by the Reporting Person by 21,500 option shares and 14,200 RSUs, respectively. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-03-01 | A | A | 21,500 | $0.00 | 21,500 | D | $12.25 · — to 2033-03-01 | 21,500 Common Stock | (F2) The Reporting Person's original Form 4, filed on March 3, 2023, is being amended by this Form 4A solely to correct an administrative error, which misreported a grant that occurred on March 1, 2023 as a total of 43,000 option shares and 28,400 RSUs, when in fact 21,500 option shares and 14,200 RSUs were granted as of that date, accurately reflecting that these grants are semi-annual. As a result of this administrative error, the number of shares beneficially owned by the Reporting Person following the corrected transaction reflects a reduction by 50% in the number of RSUs and option shares, respectively, reported as beneficially owned by the Reporting Person by 21,500 option shares and 14,200 RSUs, respectively. (F3) 25% of the option shares shall vest and become exercisable on March 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2027. |